AR030516A1 - Uso de una combinacion de salmeterol y fluticasona - Google Patents

Uso de una combinacion de salmeterol y fluticasona

Info

Publication number
AR030516A1
AR030516A1 ARP010104122A ARP010104122A AR030516A1 AR 030516 A1 AR030516 A1 AR 030516A1 AR P010104122 A ARP010104122 A AR P010104122A AR P010104122 A ARP010104122 A AR P010104122A AR 030516 A1 AR030516 A1 AR 030516A1
Authority
AR
Argentina
Prior art keywords
salmeterol
fluticasona
combination
combinations
refers
Prior art date
Application number
ARP010104122A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR030516A1 publication Critical patent/AR030516A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

Se refiere al uso de las combinaciones del salmeterol y propionato de fluticasona para el tratamiento de la enfermedad pulmonar obstructiva cronica.
ARP010104122A 2000-08-31 2001-08-29 Uso de una combinacion de salmeterol y fluticasona AR030516A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22938100P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
AR030516A1 true AR030516A1 (es) 2003-08-20

Family

ID=22860986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104122A AR030516A1 (es) 2000-08-31 2001-08-29 Uso de una combinacion de salmeterol y fluticasona

Country Status (24)

Country Link
US (1) US20040009963A1 (es)
EP (1) EP1313484A2 (es)
JP (1) JP2004507494A (es)
KR (1) KR20030031997A (es)
CN (1) CN1449288A (es)
AP (1) AP2003002753A0 (es)
AR (1) AR030516A1 (es)
AU (1) AU2001284236A1 (es)
BG (1) BG107596A (es)
BR (1) BR0113555A (es)
CA (1) CA2420532A1 (es)
EA (1) EA200300152A1 (es)
EC (1) ECSP034487A (es)
HU (1) HUP0303755A2 (es)
IL (1) IL154403A0 (es)
MA (1) MA25834A1 (es)
MX (1) MXPA03001752A (es)
NO (1) NO20030899L (es)
OA (1) OA12370A (es)
PE (1) PE20020387A1 (es)
PL (1) PL365582A1 (es)
SK (1) SK2302003A3 (es)
WO (1) WO2002017894A2 (es)
ZA (1) ZA200301475B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
DK1658063T3 (da) * 2003-08-06 2014-05-12 Galephar M F Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer
TR200907913A2 (tr) * 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR200909791A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
WO2014007781A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20160158149A1 (en) * 2013-04-29 2016-06-09 Sanofi Sa Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
AU2023324461A1 (en) * 2022-08-08 2025-02-06 Verona Pharma Plc Ensifentrine (rpl-554) for decreasing the frequency and/or severity of copd exacerbations
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Also Published As

Publication number Publication date
OA12370A (en) 2004-03-19
SK2302003A3 (en) 2003-08-05
MXPA03001752A (es) 2003-06-04
PE20020387A1 (es) 2002-06-24
EA200300152A1 (ru) 2003-08-28
HUP0303755A2 (hu) 2004-04-28
NO20030899D0 (no) 2003-02-26
BG107596A (bg) 2004-01-30
US20040009963A1 (en) 2004-01-15
ECSP034487A (es) 2003-03-31
PL365582A1 (en) 2005-01-10
WO2002017894A3 (en) 2002-08-08
IL154403A0 (en) 2003-09-17
NO20030899L (no) 2003-04-28
WO2002017894A2 (en) 2002-03-07
BR0113555A (pt) 2003-07-22
MA25834A1 (fr) 2003-07-01
CN1449288A (zh) 2003-10-15
AU2001284236A1 (en) 2002-03-13
ZA200301475B (en) 2004-05-24
CA2420532A1 (en) 2002-03-07
KR20030031997A (ko) 2003-04-23
JP2004507494A (ja) 2004-03-11
AP2003002753A0 (en) 2003-06-30
EP1313484A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
AR030516A1 (es) Uso de una combinacion de salmeterol y fluticasona
AR022609A1 (es) Combinaciones de un agonista de beta-2 y un esteroide
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
CY2016031I2 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
AR028238A1 (es) Tratamiento para el tabaco
AR028423A1 (es) Inhibidores de la replicacion del hiv
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
PA8537901A1 (es) Derivados de eteres utiles como agentes inhibidores de las isozimas pde4
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
ATE276244T1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
DE60131349D1 (de) Wegwerfhöschen
DE60125877D1 (de) Wegwerfhöschen
ITMI20040928A1 (it) Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
AR028355A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
DE60105336D1 (de) Wegwerfhöschen
DE60105369D1 (de) Wegwerfhöschen
EP1594435A4 (en) INHIBITION OF HIV-1 REPLICATION BY TREATMENT OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
UY26912A1 (es) Uso de una combinación de salmeterol y fluticasona
PT1865966E (pt) Uso de fármacos anti-inflamatórios não esteróides por inalação no tratamento de bronquite aguda e crónica
PT1276495E (pt) Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas
IT1318516B1 (it) Derivati 2-amminotetralinici otticamente attivi, procedimenti per laloro preparazione e impiego terapeutico delle corrispondenti
ATA20092000A (de) Ophthalmologisches kurzkohärenz interferometer
HN2003000273A (es) Derivados heterociclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure